Patient-derived Organoids of Lung Cancer to Test Drug Response

Studien-Informationen Einschlusskriterien Studien-Rationale Geprüfte Regime

Rekrutierend

NCT-Nummer:
NCT03979170

Studienbeginn:
April 2019

Letztes Update:
07.12.2023

Wirkstoff:
-

Indikation (Clinical Trials):
Lung Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University Hospital, Geneva

Collaborator:
-

Kontakt

Veronique SERRE-BEINIER, PhD
Kontakt:
Phone: (0)223795107
Phone (ext.): +41
E-Mail: veronique.serre-beinier@hcuge.ch» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Geneva University Hospitals
1205 Geneva
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Veronique SERRE-BEINIER, PhD
Phone: 223795107
Phone (ext.): 41
E-Mail: veronique.serre-beinier@hcuge.ch» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The aim of the project is to use a combination of patient-derived organoid models:

- To amplify tumour tissue to obtain enough material for genomic and histological analysis

- to characterize the lung cancer sub-type

- To predict treatment (non)response.

The following points will be addressed:

1. First, the investigators plan to establish and characterize formation of organoids from

biopsies of patients with lung cancer: in spheroids, in the 3D cellular model

OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM).

Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared

to the original tumour.

2. Second, the investigators will test the chemoresponse (chemosensitivity and

chemoresistance) of organoids to anti-cancer treatment.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically proven lung cancer

- Age ≥ 18

- Written informed and signed consent

- Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion Criteria:

- Less than 18 years of age

- Not able to give informed consent (language, intellectual capacities, etc.)

- Not accessible to biopsy and/or surgery sample

- Not enough lung tissue for a histological analysis or the remaining lung tissue is not

enough to perform a routine pathological analysis.

Studien-Rationale

Primary outcome:

1. Patient-derived organoid establishment (Time Frame - 3 years):
Successful generation of lung cancer organoids (growth of lung tumoral cells). The rate of successful generation of lung cancer organoids could vary with the age of the patient, the histological and molecular subtype of lung cancer

2. Patient-derived organoid validation (Time Frame - 5 years):
Proportion of patient-derived organoids that are histologically and genetically identical to the source tumour

Secondary outcome:

1. Drug sensitivity (Time Frame - 2019 - 2023):
Drug sensitivity of patient-derived tumour organoids (drug screening and chemotherapy resistance test) Secondary drug effects on patient-derived normal lung organoids

2. Prediction of the response to treatment by the patient-derived organoids (Time Frame - 2020 - 2025):
The drug sensitivity was tested on patient-derived tumour organoids, which is compared with clinical response of the chemo- or targeted therapy treatment.

Geprüfte Regime

Lung tumor resection:
lung tumor resection

Quelle: ClinicalTrials.gov

Sie können folgenden Inhalt einem Kollegen empfehlen:

"Patient-derived Organoids of Lung Cancer to Test Drug Response"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!